Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

This research study is for people with metastatic castrate-resistant prostate cancer (mCRPC). Zanzalintinib is a new drug that shows activity in mCRPC with soft tissue or visceral metastases who have progressed on prior treatment. Participants can stay in the research for up to 24 months as long as they experience clinical benefit from it. The purpose of this study is to learn if Zanzalinitib is effective in treating metastatic castrate-resistant prostate cancer.

NCT Number	NCT07608718
Lead Sponsor	Pedro Barata, MD, MSc
Conditions	Metastatic Castration-resistant Prostate Cancer
Enrollment	19 participants
Start Date	2026-09
Primary Completion	2029-05 (estimated)
Study Completion	2030-05 (estimated)
Updated on ClinicalTrials.gov	2026-05-27